InnaVirVax announces the launch of the first clinical trial on VAC-3S immunotherapy for HIV-1 infections

07-Mar-2012 - France

InnaVirVax, a biopharmaceutical company specialized in the research and development focused on immune dysregulation, announced that it has initiated a Phase I/IIa clinical trial on its VAC-3S immunotherapy agent for the treatment of HIV infections. This " first-in-class " therapy seeks to protect the immune system of patients infected with HIV-1, and this trial is starting only a little more than three years since InnaVirVax  started its operations.

This phase I/IIa clinical trial is being carried out in two major clinical reference centers in Paris, France: the Pitié-Salpêtrière and Cochin Hospitals, and involves 24 patients infected with HIV-1 whose viral load is controlled under antiretroviral therapy, who will receive of escalating doses of treatment.

The primary endpoint is the safety of this immunotherapy. The immunogenicity of the candidate drug is also being studied, as are its effects on laboratory markers of HIV infection (notably the CD4 count, viral load and markers of cellular activation). Patients will be immunized and then followed for one year. The primary endpoint of the study will be reviewed one month after the last treatment of each patient.

This clinical trial has been awarded a grant of €600,000 from OSEO, the French government-backed agency that supports innovation. This recognition has strengthened InnaVirVax in its resolve to develop VAC-3S.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance